Imagine you have a toolbox full of different tools, but you’re not sure which one will fix a particular problem. That’s the situation we’re facing when it comes to finding a treatment for Alzheimer’s disease (AD). Researchers have discovered that there is a connection between type 2 diabetes and AD, with diabetes increasing the risk of developing AD. This has led scientists to explore the use of clinical antidiabetic medication as a potential therapy for AD. However, while these medications show promise in basic research, their effectiveness in clinical trials has been limited. In this review, researchers discuss the opportunities and challenges that arise when translating antidiabetic medication from basic discovery to therapeutic development for AD. By understanding the progress made so far, we can offer hope to patients with specific types of AD caused by high blood glucose levels or insulin resistance. If you’re curious about this exciting field of research, dive into the full article to learn more!
Alzheimer’s disease (AD) is a common neurodegenerative disease. Type 2 diabetes mellitus (T2DM) appears to increase and contributing to the risk of AD. Therefore, there is increasing concern about clinical antidiabetic medication used in AD. Most of them show some potential in basic research, but not in clinical research. So we reviewed the opportunities and challenges faced by some antidiabetic medication used in AD from basic to clinical research. Based on existing research progress, this is still the hope of some patients with special types of AD caused by rising blood glucose or/and insulin resistance.
Dr. David Lowemann, M.Sc, Ph.D., is a co-founder of the Institute for the Future of Human Potential, where he leads the charge in pioneering Self-Enhancement Science for the Success of Society. With a keen interest in exploring the untapped potential of the human mind, Dr. Lowemann has dedicated his career to pushing the boundaries of human capabilities and understanding.
Armed with a Master of Science degree and a Ph.D. in his field, Dr. Lowemann has consistently been at the forefront of research and innovation, delving into ways to optimize human performance, cognition, and overall well-being. His work at the Institute revolves around a profound commitment to harnessing cutting-edge science and technology to help individuals lead more fulfilling and intelligent lives.
Dr. Lowemann’s influence extends to the educational platform BetterSmarter.me, where he shares his insights, findings, and personal development strategies with a broader audience. His ongoing mission is shaping the way we perceive and leverage the vast capacities of the human mind, offering invaluable contributions to society’s overall success and collective well-being.